Exact Sciences Q4 EPS Estimate Decreased by Leerink Partnrs

Exact Sciences Co. (NASDAQ:EXAS) – Equities researchers at Leerink Partnrs cut their Q4 2024 EPS estimates for Exact Sciences in a research report issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of ($0.31) for the quarter, down from their previous forecast of ($0.30). The consensus estimate for Exact Sciences’ current full-year earnings is ($1.10) per share. Leerink Partnrs also issued estimates for Exact Sciences’ Q2 2025 earnings at $0.02 EPS.

Several other analysts also recently weighed in on EXAS. Citigroup decreased their price target on shares of Exact Sciences from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Piper Sandler decreased their price target on shares of Exact Sciences from $85.00 to $75.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. Craig Hallum decreased their price target on shares of Exact Sciences from $82.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Canaccord Genuity Group decreased their price target on shares of Exact Sciences from $95.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Evercore ISI decreased their price target on shares of Exact Sciences from $80.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $72.76.

Exact Sciences Stock Up 1.5 %

Shares of NASDAQ EXAS opened at $55.98 on Thursday. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.12 and a quick ratio of 1.93. The company has a market cap of $10.36 billion, a P/E ratio of -47.85 and a beta of 1.24. Exact Sciences has a 1 year low of $40.62 and a 1 year high of $79.62. The firm has a 50-day simple moving average of $57.54 and a two-hundred day simple moving average of $59.40.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Tuesday, November 5th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The firm had revenue of $708.66 million during the quarter, compared to the consensus estimate of $716.80 million. Exact Sciences had a negative return on equity of 6.17% and a negative net margin of 7.95%. Exact Sciences’s quarterly revenue was up 12.8% compared to the same quarter last year.

Insider Activity

In other Exact Sciences news, CEO Kevin T. Conroy bought 19,500 shares of the firm’s stock in a transaction that occurred on Wednesday, November 13th. The stock was bought at an average cost of $51.35 per share, for a total transaction of $1,001,325.00. Following the completion of the transaction, the chief executive officer now directly owns 1,074,191 shares of the company’s stock, valued at approximately $55,159,707.85. This trade represents a 1.85 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.36% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EXAS. Chicago Partners Investment Group LLC raised its position in shares of Exact Sciences by 1.7% in the third quarter. Chicago Partners Investment Group LLC now owns 9,261 shares of the medical research company’s stock worth $651,000 after acquiring an additional 158 shares during the period. Perigon Wealth Management LLC raised its position in shares of Exact Sciences by 3.2% in the fourth quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock worth $474,000 after acquiring an additional 264 shares during the period. Amalgamated Bank raised its position in shares of Exact Sciences by 2.7% in the second quarter. Amalgamated Bank now owns 10,937 shares of the medical research company’s stock worth $462,000 after acquiring an additional 284 shares during the period. Huntington National Bank raised its position in shares of Exact Sciences by 838.1% in the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock worth $27,000 after acquiring an additional 352 shares during the period. Finally, CIBC Asset Management Inc raised its position in shares of Exact Sciences by 6.1% in the third quarter. CIBC Asset Management Inc now owns 6,489 shares of the medical research company’s stock worth $442,000 after acquiring an additional 371 shares during the period. 88.82% of the stock is currently owned by institutional investors and hedge funds.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.